Previous 10 | Next 10 |
Noteworthy events during the week of September 1 - 9 for healthcare investors. More news on: Synlogic, Inc., Orchard Therapeutics plc, Zosano Pharma Corporation, Healthcare stocks news, , Read more ...
BOSTON and LONDON, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
The FDA has signed off on Seelos Therapeutics' ( SEEL +7.3% ) IND for a Phase 2b/3 clinical trial evaluating SLS-005 (trehalose) in patients with mucopolysaccharidosis type III (Sanfilippo syndrome), an inherited disorder characterized by delayed speech and behavioral problems that is ...
Orchard Therapeutics plc (ORTX) Q2 2019 Earnings Conference Call August 08, 2019 08:00 AM ET Company Participants Renee Leck - Director, Investor Relations Mark Rothera - President, Chief Executive Officer Bobby Gaspar - Chief Scientific Officer Frank Thomas - Chief Financial O...
Orchard Therapeutics (NASDAQ: ORTX ): Q2 GAAP EPS of -$0.56 misses by $0.20 . More news on: Orchard Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Metachromatic Leukodystrophy (MLD) MAA Submission and Initiation of ADA-SCID Rolling BLA Expected in the First Half of 2020; OTL-103 Recently Granted RMAT Designation for Wiskott-Aldrich Syndrome (WAS) MLD and Mucopolysaccharidosis Type I (MPS-I) Abstracts Accepted for Oral Presentati...
BOSTON and LONDON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
BOSTON and LONDON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
Three-Year Registrational Data Set to be Presented by Year End 2019 Regulatory Submissions Planned in the U.S. and Europe for 2021 BOSTON and LONDON, July 29, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicate...
BOSTON and LONDON, June 10, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....